These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-003328-12 A multi-centre, randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo in patients with thrombocytosis seco... 2010-01-31 due-trials
Reported results 2006-004608-37 A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject) with placebo in patients with chronic heart failure and iron de... 2009-07-17 due-trials
Reported results Terminated 2007-001517-41 Comparative study of the efficacy and tolerability of iron polymaltose complex film-coated tablets with folic acid (Maltofer® Fol film-coated tablets) compared to a generic iron sulphate product in pr... 2009-09-11 due-trials
Not reported 2007-003565-40 An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease und... 2007-12-13 due-trials
Reported results 2008-001503-26 EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure (EFFICACY-HF) 2009-10-31 due-trials
Reported results 2008-002333-75 A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT®) versus ir... 2009-12-10 due-trials
Reported results 2008-003591-22 A multi-centre, randomised, prospective, single-blinded, controlled study to investigate the efficacy and safety of a standardised maintenance dosage regimen of intravenous ferric carboxymaltose (FERI... 2010-08-30 due-trials
Reported results 2008-004748-36 An open-label, randomized, active controlled multi center phase II dose finding study to evaluate the ability of PA21 to lower serum phosphate levels and the tolerability in patients with chronic kidn... 2009-10-05 due-trials
Reported results Terminated 2009-009983-29 A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients 2010-01-12 due-trials
Reported results 2009-015579-28 An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High- and Low-dosage Regimens) versus Oral Iron f... 2013-02-12 due-trials
Reported results 2009-015766-56 A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-... 2011-06-01 due-trials
Reported results 2009-015767-14 A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies and ... 2012-11-09 due-trials
Reported results 2009-017658-11 An open-label, multicentre, randomised, 2-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemi... 2014-05-16 due-trials
Reported results 2009-017737-21 A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient ... 2011-11-08 due-trials
Reported results 2010-018838-45 A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for RLY5016 in Heart Failure Patients with Chronic Kidney Disease 2010-11-05 due-trials
Reported results 2010-022011-19 An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomised Compa... 2012-04-09 due-trials
Reported results 2010-022012-40 An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared with Sevelamer Carbonate in Dial... 2012-10-25 due-trials
Reported results 2011-000165-12 A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of RLY5016 in the Treatment of Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy Receivi... 2013-06-17 due-trials
Reported results 2011-000603-40 Multicentre, prospective, randomised, 2-arm study to assess the impact of ferric carboxymaltose on exercise capacity in chronic heart failure patients with iron deficiency 2016-05-18 due-trials
Reported results 2011-001695-19 A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose with Placebo in Patients with Chronic Heart Failure and Iron Deficiency 2014-02-13 due-trials
Reported results 2012-001956-20 A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia 2013-08-06 due-trials
Reported results 2013-000574-30 A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron Def... 2015-09-01 due-trials
Reported results 2015-004155-43 An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Ad... 2019-02-21 due-trials
Reported results 2016-001467-36 A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Fail... 2020-07-21 due-trials
Reported results 2016-002657-38 A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chroni... 2018-11-27 due-trials
Reported results 2016-002785-31 A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with Ch... 2022-05-13 due-trials
Completed, but no date 2018-002293-44 A Pragmatic randomized study to evaluate the comparative effectiveness of Akynzeo® and Standard of care (including Emend®) for the prevention of nausea and vomiting (CINV) in cancer patients receiving... bad-data
Ongoing 2018-003184-65 POREIIL - Postoperative replacement of intraoperative iron losses POREIIL - Postoperativer Ersatz von intraoperativen Eisenverlusten not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-005030-38 A Multicenter, Double-blind, Placebo controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System ... 2021-09-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-002221-29 A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VI... 2021-11-03 bad-data
Reported results 2019-004696-40 A phase IV, randomized, double blind cross-over study to evaluate palatability of Patiromer compared to Sodium Polystyrene Sulfonate in healthy subjects 2020-09-03 due-trials
Ongoing 2020-005072-34 A Phase 2a, double-blind, randomised, placebo controlled, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease (ViSion Serenity) not-yet-due
Reported results Terminated 2021-001639-23 A Phase 2b, double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent ß-thalassaemia Studio d... 2022-09-29 due-trials